Pacira BioSciences Q2 2024 Adj. EPS $0.89 Beats $0.69 Estimate, Sales $178.023M Beat $172.497M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pacira BioSciences (NASDAQ:PCRX) reported Q2 2024 earnings of $0.89 per share, beating the analyst estimate of $0.69 by 28.99%. Sales were $178.023 million, surpassing the $172.497 million estimate. Both earnings and sales showed significant year-over-year growth.
July 30, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacira BioSciences reported strong Q2 2024 earnings and sales, both beating analyst estimates and showing significant year-over-year growth.
The company's earnings per share (EPS) and sales both exceeded analyst expectations, indicating strong financial performance. This positive earnings report is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100